+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Physiomics Plc (PYC) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 47 Pages
  • December 2024
  • GlobalData
  • ID: 1315571
Physiomics Plc (PYC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Physiomics Plc (Physiomics) provides consulting services to pharmaceutical companies in the areas of computational biology and quantitative pharmacology. The company’s proprietary technology platform, Virtual Tumour, uses computer modeling to predict the effects of cancer drugs and treatments. Physiomics offers model-based drug development services, which include population (Pharmacokinetics and Pharmacodynamics) PKPD analysis of clinical data, back-translational analysis, and optimal design of future studies. It also has Quantitative Systems Pharmacology which involves the combination of PK/PD of a therapeutic agent with the mechanistic model and a large quantitative experimental drug data. Physiomics is headquartered in Oxfordshire, the UK.

Physiomics Plc Key Recent Developments

  • Dec 12, 2024: Physiomics Announces Contract Award with Numab Therapeutics
  • Dec 05, 2024: Physiomics Announces Contract Award on 5 December 2024
  • Nov 04, 2024: Physiomics Reports Senior Management Changes
  • Oct 17, 2024: Physiomics Announce Contract Award

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Physiomics Plc - Key Facts
  • Physiomics Plc - Key Employees
  • Physiomics Plc - Key Employee Biographies
  • Physiomics Plc - Major Products and Services
  • Physiomics Plc - History
  • Physiomics Plc - Company Statement
  • Physiomics Plc - Locations And Subsidiaries
  • Head Office
Section 2 - Company Analysis
  • Company Overview
  • Physiomics Plc - Business Description
  • Physiomics Plc - Corporate Strategy
  • Physiomics Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Physiomics Plc - Strengths
  • Physiomics Plc - Weaknesses
  • Physiomics Plc - Opportunities
  • Physiomics Plc - Threats
  • Physiomics Plc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Physiomics Plc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Dec 12, 2024: Physiomics Announces Contract Award with Numab Therapeutics
  • Dec 05, 2024: Physiomics Announces Contract Award on 5 December 2024
  • Nov 04, 2024: Physiomics Reports Senior Management Changes
  • Oct 17, 2024: Physiomics Announce Contract Award
  • Oct 02, 2024: Physiomics New Services Launch and Website Update
  • Sep 27, 2024: Physiomics Reports Final Results for Year Ended June 30, 2024
  • Sep 19, 2024: Physiomics: Notice of Results and Investor Presentation via Investor Meet Company
  • Jun 14, 2024: Physiomics Adds Modeling and Data Science Functionality to DoseMe's Precision Dosing Platform
  • Jun 13, 2024: Physiomics Announces Contract Award on 13 June 2024
  • Jun 07, 2024: Physiomics Plc Announces Contract Award
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Physiomics Plc, Key Facts
  • Physiomics Plc, Key Employees
  • Physiomics Plc, Key Employee Biographies
  • Physiomics Plc, Major Products and Services
  • Physiomics Plc, History
  • Physiomics Plc, Key Competitors
  • Physiomics Plc, Ratios based on current share price
  • Physiomics Plc, Annual Ratios
  • Physiomics Plc, Interim Ratios
  • Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Physiomics Plc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Physiomics Plc, Performance Chart (2020 - 2024)
  • Physiomics Plc, Ratio Charts
  • Physiomics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Physiomics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • e-Therapeutics Plc
  • Avacta Group Plc
  • Elekta AB
  • Cyprotex Ltd